Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587275 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
A Phase 2 study, sponsored by Ocera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00587275 is a Phase 2 study that was terminated before completion, run by Ocera Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT00587275, a Phase 2 study, was terminated before completion, sponsored by Ocera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this project is to test how safe and how well AST-120, an investigational product, works in treating too much acid in the stomach. Patients will be randomly assigned to one of two groups, AST-120 or a placebo for the first four weeks of the study. The patients will be switched to the other group (AST-120 or placebo)for the following four weeks.
Interventions
- DRUG AST-120
- DRUG Celphere CP-305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587275
The ClinicalTrials.gov registry entry for NCT00587275 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocera Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AST-120 is the first listed.
NCT00587275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587275 about?
NCT00587275 is a clinical study titled "Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI". The purpose of this project is to test how safe and how well AST-120, an investigational product, works in treating too much acid in the stomach. Patients will be randomly assigned to one of two groups, AST-120 or a placebo for the first four weeks of the study. The patients will be switched to the ...
What is the current status of trial NCT00587275?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2007-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00587275?
The interventions under investigation include: AST-120 (DRUG), Celphere CP-305 (DRUG).
Who is sponsoring clinical trial NCT00587275?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.